Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00307164 · ClinicalTrials.gov registry record · Phase 2
Effects of a Uridine Supplement on HIV Infected Adults With Lipoatrophy
A Phase 2 study, sponsored by National Institute of Allergy and Infectious Diseases (NIAID).
- Completed
- Registry status
- Phase 2
- Development phase
- 167
- Enrollment target
NCT00307164 is a Phase 2 study that has completed, run by National Institute of Allergy and Infectious Diseases (NIAID). The registered enrollment target is 167 participants.
The verdict
NCT00307164, a Phase 2 study, has completed, sponsored by National Institute of Allergy and Infectious Diseases (NIAID).
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 167 participants
- Enrollment target
Study Summary
Lipoatrophy, the loss of body fat from particular areas of the body, is a common side effect of antiretroviral therapy (ART). The purpose of this study was to determine the effectiveness of uridine supplementation in treating HIV infected individuals on stable ART with lipoatrophy.
Interventions
- DRUG NucleomaxX
- DRUG NucleomaxX placebo
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 167 participants |
| Start Date | 2006-09 |
| Est. Completion | 2008-12 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00307164
The ClinicalTrials.gov registry entry for NCT00307164 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 167 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is National Institute of Allergy and Infectious Diseases (NIAID), which has 2,006 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which NucleomaxX is the first listed.
NCT00307164 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00307164 about?
NCT00307164 is a clinical study titled "Effects of a Uridine Supplement on HIV Infected Adults With Lipoatrophy". Lipoatrophy, the loss of body fat from particular areas of the body, is a common side effect of antiretroviral therapy (ART). The purpose of this study was to determine the effectiveness of uridine supplementation in treating HIV infected individuals on stable ART with lipoatrophy.
What is the current status of trial NCT00307164?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 167 participants. The study started on 2006-09. Estimated completion is 2008-12.
What interventions are being tested in trial NCT00307164?
The interventions under investigation include: NucleomaxX (DRUG), NucleomaxX placebo (DRUG).
Who is sponsoring clinical trial NCT00307164?
This trial is sponsored by National Institute of Allergy and Infectious Diseases (NIAID), which has 2,006 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.